$4.95+0.38 (+8.32%)
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.
Quoin Pharmaceuticals, Ltd. in the Healthcare sector is trading at $4.95. Wall Street consensus targets $29.75 (4 analysts), implying a +501.0% move over the next 12 months. The stock is currently near its 52-week low of $4.11, remaining 47.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lo...
Looking at Quoin Pharmaceuticals, Ltd.'s ( NASDAQ:QNRX ) insider transactions over the last year, we can see that...
Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F
Quoin Pharmaceuticals (QNRX) shares jumped nearly 170% in recent Friday trading after the company sa